Article

Bayer Wins Early US Approval for Colon Cancer Drug

The U.S. Food and Drug Administration on Thursday approved a new drug for advanced colon cancer developed by Bayer AG, a month ahead of the agency's expected action date for a decision.

The drug, to be sold under the brand name Stivarga, was approved to treat colon cancer that has progressed after prior treatment or that has spread to other parts of the body, the agency said.

Read the full story: reut.rs/QyWLff

Source: Reuters

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
Mehmet Oz, MD, MBA
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Nicole Bajic, MD
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo